`
`From:
`Sent:
`To:
`Subject:
`
`Dear Nathan Beaver,
`
`Stewart, Kendra <Kendra.Stewart@fda.hhs.gov>
`Thursday, October 12. 2017 10:54 AM
`Beaver, Nate
`RE: Orange Book Listing Date
`
`Per Orange Book records, the '507 patent was listed on the Orange Book website on 52'192'2016 and the '240 patent was
`listed on 619f2016.
`
`Regards,
`
`CAPT Kendra 5. Stewart, It.Ph., Phat-mt).
`US Public Health Service
`Supervisor: Orange Book Staff
`Center for Drug Evaluation and Research
`Office of Generic Drugs
`US. Food and Drug Administration
`Tel: 240-4026?97
`
`ORANGE BOOK QUESTIONS:Wm
`wEasnE:Wm
`
`0.5. 7000810“
`All IIIIS'II ‘7"!!!
`
`From:Wm [Miriam]
`Sent: Wednesday, October 11, 2017 4:26 PM
`To: Stewart, Kendra
`Subject: Orange Book Listing Date
`
`Dr. Stewart.
`
`This follows up on a voicemail I left you earlier today. We represent United Therapeutics {UT} and are trying to confirm
`the date of publication in the Orange Book [i.e., the date the electronic OB was updated and patent information was
`publicly available} for two US Patents that were submitted by UT:
`
`US Patent Nos. 9,339,507 and 9,358,240
`
`These were submitted for listing by UT on 61812016 for Twaso with re5pect to the ‘240 patent and on 5}17[2016 with
`respect to the ‘507 patent .
`
`lam hoping that Orange Book Staff can confirm this information and respond by email with the actual date oflisting in
`the OB.
`
`Thank you.
`
`UNITED THERAPEUTICS, EX. 2030
`WATSON LABORATORIES V. UNITED THERAPEUTICS, IPR2G1T-fl1622
`Page 1 of2
`
`
`
`Best regards.
`
`Nate
`
`Nathan A. Beaver, Partner
`Foley Bl Lardner LLP — 3000 K St. NW, Suite 600
`Washington, DC 20007
`(p) 202-295-4039 — (fl 202-6?2-5399
`nheaggrflfolelgom
`
`The preceding email message may be confidential or protected by the attorney-client privilege. It is not intended
`for transmission to, or receipt by, any unauthorized persons. If you have received this message in error, please
`(i) do not read it, (ii) reply to the sender that you received the message in error, and (iii) erase or destroy the
`message. Legal advice contained in the preceding message is solely for the benefit of the Foley 35 Lardner LLP
`client(s) represented by the Firm in the particular matter that is the subject of this message, and may not be
`relied upon by any other party.
`
`UNITED THERAPEUTICS, EX. 2030
`WATSON LABORATORIES V. UNITED THERAPEUTiCS, lPR2017-01622
`Page 2 of 2
`
`